Bibliography
- De Clercq E. Antivirals and antiviral strategies. Nature Rev Microbiol 2004;21:704-20
- Richman DD. HIV chemotherapy. Nature 2001;410:995-1001
- Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002-7
- Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem 2002;17:69-76
- Scozzafava A, Owa T, Mastrolorenzo A, Anticancer and antiviral sulfonamides. Curr Med Chem 2003;10:925-53
- Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-43
- Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995;270:11703-6
- Cocchi F, De Vico AL, Garzino-Demo A, Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-15
- Tomaras GD, Greenberg ML. Mechanisms for HIV-1 Entry: current strategies to interfere with this step. Curr Infect Dis Rep 2001;3:93-9
- Blair WS, Lin PF, Meanwell NA, Wallace OB. HIV-1 entry - an expanding portal for drug discovery. Drug Discov Today 2000;5:183-94
- Mastrolorenzo A, Scozzafava A, Supuran CT. Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. Expert Opin Ther Pat 2001;11:1245-52
- Casini A, Scozzafava A, Supuran CT. Sulfonamide derivatives with protease inhibitory action as anticancer, antiinflammatory and antiviral agents. Expert Opin Ther Pat 2002;12:1307-27
- Kwong PD, Wyatt R, Robinson J, Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59
- Stantchev TS, Broder CC. Human immunodeficiency virus type-1 and chemokines: beyond competition for common cellular receptors Cytokine Growth Factors Rev 2001;12:219-43
- Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002;42:469-99
- Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001;291:884-8
- Carter NJ, Keating GM. Maraviroc. Drugs 2007;67:2277-88
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 2008;7:168-81
- Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467-74
- Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
- Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199-229
- Supuran CT, Vullo D, Manole G, Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49-68